GCC PNH Pricing Strategy Model

The GCC has no unified HTA authority for PNH therapies. Saudi Arabia's NPHC, the National Programme for Rare and Genetic Diseases, functions as the de facto regional reference instead. UAE, Qatar, Kuwait, Oman, and Bahrain typically track an NPHC coverage decision within six to eighteen months rather than running independent assessments. NPHC already covers eculizumab and ravulizumab under defined clinical criteria. Iptacopan does not have that precedent yet. It is working through SFDA's Priority Review pathway for rare-disease products, a route that targets twelve to eighteen months post-FDA submission versus eighteen to twenty-four in the standard lane, and NPHC evaluation has not begun.

The pricing mechanism itself is a cascade, not a negotiation. SFDA anchors to whichever EU comparator prices lowest, commonly Portugal, Greece, or Romania, then layers on a further ten to twenty percent negotiation discount before a GCC tender is signed. That mechanism already shows in anti-C5 pricing: GCC tenders run forty to sixty percent of US WAC equivalent, roughly SAR 60,000 to 90,000 per infusion against a US WAC equivalent of SAR 150,000 to 200,000. Iptacopan is expected to land in the same forty to fifty-five percent band once SFDA registration completes. Our price ladder models the specific EU anchor most likely to set that floor, since the anchor market matters as much as the GCC negotiation itself.

Every AXLRx pricing model is built from primary regulatory sources (SFDA, NPHC, Saudi MOH) and live registration-tracking documentation, not secondary summaries. Findings are independently verified before inclusion.

PNH GCC pricing sources: SFDA drug registration guidelines 2023, NPHC programme documentation, SFDA Priority Review guidelines 2020, SFDA rare disease regulation 2020, and Saudi MOH drug procurement data 2023.